靶向ALK的克唑替尼治疗儿童间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤:儿童肿瘤学组研究
本研究评估克唑替尼在复发/难治性ALK阳性间变性大细胞淋巴瘤(ALCL)和转移性或不可手术的ALK阳性炎性肌纤维母细胞瘤(IMT)患者中的疗效与安全性。26例ALCL和14例IMT患者接受口服克唑替尼每日两次。ALCL165组和ALCL280组的总缓解率分别为83%和90%,IMT组为86%。
要点
- 克唑替尼在复发/难治性ALK阳性ALCL中显示出高缓解率,ALCL165组83%,ALCL280组90%。
- 克唑替尼在转移性或不可手术的ALK阳性IMT中总缓解率为86%。
- 最常见药物相关不良事件为中性粒细胞计数下降,ALCL165组33%,ALCL280组70%,IMT组43%。
核心结论
- 克唑替尼在复发ALCL和转移性或不可切除IMT患者中产生稳健且持久的临床缓解,突显了ALK通路在这些疾病中的重要性。
研究设计与样本
- 本研究纳入26例复发/难治性ALK阳性ALCL患者和14例转移性或不可手术的ALK阳性IMT患者,接受克唑替尼口服每日两次治疗,研究目标为疗效和安全性评估,并开展ALCL患者NPM-ALK融合转录本的连续检测相关研究。
主要发现
- ALCL165组(剂量165 mg/m2)的总缓解率为83%,ALCL280组(剂量280 mg/m2)为90%,IMT组(剂量100、165和280 mg/m2/次)为86%。
- 完全缓解率:ALCL165组83%(5/6),ALCL280组80%(16/20),IMT组36%(5/14)。
- 部分缓解率:ALCL165组0%(0/6),ALCL280组10%(2/20),IMT组50%(7/14)。
- 中位治疗持续时间分别为ALCL165组2.79年、ALCL280组0.4年、IMT组1.63年,12例患者停止方案治疗以进行移植。
- 最常见药物相关不良事件为中性粒细胞计数下降,ALCL165组33%,ALCL280组70%,IMT组43%;大多数ALCL患者治疗期间NPM-ALK水平下降。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs). We assessed the activity of the ALK inhibitor crizotinib in patients who had no known curative treatment options at diagnosis or with relapsed/recurrent disease. Methods In this study, 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT received crizotinib orally twice daily. Study objectives were measurement of efficacy and safety. Correlative studies evaluated the serial detection of NPM-ALK fusion transcripts in patients with ALCL. Results The overall response rates for patients with ALCL treated at doses of 165 (ALCL165) and 280 (ALCL280) mg/m2 were 83% and 90%, respectively. The overall response rate for patients with IMT (treated at 100, 165, and 280 mg/m2/dose) was 86%. A complete response was observed in 83% (five of six) of ALCL165, 80% (16 of 20) of ALCL280, and 36% (five of 14) of patients with IMT. Partial response rates were 0% (none of six), 10% (two of 20), and 50% (seven of 14), respectively. The median duration of therapy was 2.79, 0.4, and 1.63 years, respectively, with 12 patients ceasing protocol therapy to proceed to transplantation. The most common drug-related adverse event was decrease in neutrophil count in 33% and 70% of the ALCL165 and ALCL280 groups, respectively, and in 43% of patients with IMT. Levels of NPM-ALK decreased during therapy in most patients with ALCL. Conclusion The robust and sustained clinical responses to crizotinib therapy in patients with relapsed ALCL and metastatic or unresectable IMT highlight the importance of the ALK pathway in these diseases.
引用
- Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017. PMID: 28787259. doi:10.1200/JCO.2017.73.4830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。